Financhill
Back

Blueprint Medicines Quote, Financials, Valuation and Earnings

Buy
58

BPMC
Blueprint Medicines

Last Price:
104.13
Seasonality Move:
6.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Blueprint Medicines Price Quote

$104.13
-0.13 (-0.79%)
(Updated: May 21, 2024 at 5:29 AM ET)

Blueprint Medicines Key Stats

Buy
58
Blueprint Medicines (BPMC) is a Buy

Day range:
$103.69 - $105.64
52-week range:
$43.89 - $111.02
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
22.71
P/B ratio:
21.01%

Volume:
462.3K
Avg. volume:
668.9K
1-year change:
90.46%
Market cap:
$6.5B
Revenue:
$249.4M
EPS:
$-4.81

How Much Does Blueprint Medicines Make?

Is Blueprint Medicines Growing As A Company?

  • What Is Blueprint Medicines's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.52%
  • What Is Blueprint Medicines's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Blueprint Medicines Stock Price Performance

What Is Blueprint Medicines 52-Week High & Low?

Blueprint Medicines Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Blueprint Medicines?

Is Blueprint Medicines Cash Flow Positive?

  • What Is BPMC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$415.4M
  • What Is Blueprint Medicines’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $186.2M
  • What Is Blueprint Medicines’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $178.4M

Blueprint Medicines Return On Invested Capital

  • Is Management Doing A Good Job?
    BPMC return on invested capital is -60.94%
  • What Is Blueprint Medicines Return On Assets?
    ROA measures how assets are converting to revenues and is -26.11%
  • What Is BPMC Return On Equity?
    ROE is a measure of profitability and is -105.27%

Blueprint Medicines Earnings Date & Stock Price

Blueprint Medicines Competitors

  • Who Are Blueprint Medicines's Competitors?
    Below is a list of companies who compete with Blueprint Medicines or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Apellis Pharmaceuticals Inc (APLS)
    • Biomarin Pharmaceutical Inc (BMRN)
    • Cytokinetics Inc (CYTK)
    • Ligand Pharmaceuticals Inc (LGND)

Blueprint Medicines Dividend Yield

Data Unavailable

Blueprint Medicines Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 20.93%
Revenue: 51.87% 18.01%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 4
Sell Recommendations: 1
Price Target: 119.41
Upside from Last Price: 14.53%

Major Shareholders

  • How many BPMC shares are owned by institutional investors?
    112.1M BPMC shares are owned by institutional investors
  • How many BPMC shares are owned by insiders?
    1.4M BPMC shares are owned by insiders